Boston Scientific has disclosed insider trading activity — David A. Pierce, senior vice president and president, endoscopy of Boston Scientific unloaded 5,000 shares at an average price of $12.90 on Dec. 8, according to a Stafford Daily report.
The total amount of the transaction was worth $64,500, noted the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Boston Scientific is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties, including interventional cardiology, endoscopy, peripheral interventions and urology/women's health, according to the report.
More articles on GI/endoscopy:
Global endoscopy market to reach $47B by 2020: 8 key trends
GI Dynamics names Michael Dale president & CEO
Diagnostic Endoscopy Center's Dr. Stuart Waldstreicher honored